MicroPort Orthopedics Receives Long-Term ODEP Rating for its Advance® Medial-Pivot Knee System

Apollo Hospitals Saves 41 Yr Old Farmer Who Waited 91 Days for a Heart Transplant with Mitral Chip Implant

India's first two scientific papers on MitraClip have both been published from Apollo Hopsitals. Dr. Sai Satish is involved in the authorship of the APAC guidelines for MitraClip implants.

Append Medical Completes $7.4M Million Series A Round

Append Medical is a developer of the first no-implant minimally invasive solution for transcatheter Left Atrial Appendage (LAA) exclusion.  Today the company announced the...

Randomized Controlled Trial for the EkoSonic™ Endovascular System Commences

"Optimal treatment of PE is still poorly understood and there is a need for a coordinated institutional approach to this complex, life-threatening problem," said Kenneth Rosenfield, M.D., study co-lead principal investigator and section head, Vascular Medicine and Intervention, Division of Cardiology, Massachusetts General Hospital, Boston. "The lead investigators of the trial are pleased to collaborate with the PERT Consortium, which is committed to evidence-driven therapy and is proud to take part in the HI-PEITHO study, aiming to advance the care of patients with PE."

MicroPort Orthopedics, a global leader in orthopedic devices and technologies, has received a “15A” rating for its Advance® Medial-Pivot knee system from the Orthopaedic Data Evaluation Panel (ODEP).

Fifteen (15) years is the longest benchmark that ODEP assigns ratings for knee implants, providing further evidence of the long clinical heritage of the Advance® Medial-Pivot knee system. ODEP was established in 2002, and provides an independent review of clinical data to assign ratings and share information about the success of arthroplasty implants.

MicroPort Orthopedics’ medial-pivot knee systems stand on more than 20 years of clinically demonstrated history with a complete portfolio of medial-pivot design knees. The Advance® Medial-Pivot knee system was built on the latest kinematic evidence of the natural stability and motion of the knee.1 Its innovative design is carried on by MicroPort’s latest medial-pivot knee, the Evolution® Medial-Pivot knee system, which also aims to restore function by replicating natural motion and stability, and to address some of the common problems seen with traditional designs, such as anterior knee pain and quadriceps avoidance.

The design and successful clinical heritage of MicroPort Orthopedics’ medial-pivot knee systems sets them apart from the competition. A legacy of 98.8 percent survivorship over 17 years and 95 percent patient satisfaction supports its ability to restore stability and normal kinematics. This helps surgeons achieve favorable, reproducible, and long-lasting outcomes for their patients. 2-5
 
“It’s our goal at MicroPort to develop innovative products and procedures that help providers improve patient outcomes, facilitate fast recovery and a return to normal life activities,” says Irina Timmerman, the Vice President of Regulatory and Clinical Affairs at MicroPort Orthopedics. “This rating from ODEP further validates MicroPort’s medial-pivot knee systems’ ability to produce consistent and long-lasting results.”

REFERENCES

1. George A. Macheras et al. “A long term clinical outcome of the Medial Pivot Knee Arthroplasty System.” The Knee Journal, January 29, 2017.

2. Patient satisfaction at 2 months following total knee replacement using a second generation medial-pivot system: follow-up of 250 consecutive cases. Van Overschelde P et al. Ann Transl Med 2016

3. Pritchett JW. Patients prefer a bicruciate-retaining or the medial pivot total knee prosthesis. J Arthroplasty. 2011;26:224–228.

4. Miyazaki Y et al. Analysis of the Kinematics of Total Knee Prostheses With a Medial Pivot Design. J Arthroplasty. 2011; 26(7):1038-1044.

5. Lamontagne M et al.. Muscle Activity in Total Knee Arthroplasty Patients While Ascending and Descending a Ramp. Orthopaedic Proceedings, 2019. 101-B(SUPP_5): p. 59-59.

spot_img

DON'T MISS

Graham Belgrave Named to the 2021 PharmaVOICE 100 List of Distinguished Leaders

At Advanced Clinical, and from previous organizations, Belgrave serves as a mentor to several colleagues, where he challenges them to think outside of the box and take risks.

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.